Unlock the future of NSCLC treatment

DRG Disease Landscape & Forecast

Non-small-cell lung cancer – Landscape & Forecast – Disease Landscape & Forecast (G7) – report offers a comprehensive analysis of the NSCLC market, providing in-depth insights into its evolving dynamics, emerging therapeutic developments and a 10-year sales forecast. Supported by expert perspectives from 38 oncologist interviews, as well as detailed epidemiological and survey data, it delivers the strategic intelligence necessary for informed decision-making in this rapidly advancing landscape.

Request more information

Key trends in non-small-cell lung cancer treatment:

  • Dynamic market landscape: The NSCLC therapy market is highly dynamic with numerous approved therapies but still faces high unmet needs.

  • Leading immune checkpoint inhibitors: Drugs like Keytruda (Merck & Co.) dominate the field, with broad applicability across various stages and settings of NSCLC. Keytruda gained label expansions in the respectable early-stage space in 2023.

  • Innovative biomarker-targeted therapeutics: These therapies are increasingly driving market segmentation, with new entrants like Braftovi + Mektovi and Augtyro in 2023.

  • Promising drug development: With ongoing advancements in biomarker-driven and immune checkpoint inhibitor therapies, along with expected new market entrants will further intensify competition in the NSCLC market.

 

Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.

Key questions answered:

  • How will the recent and expected new market entrants shape the treatment landscapes in the various settings and stages (I-IV) of NSCLC?

  • Which therapies will dominate the commercially lucrative first-line metastatic NSCLC setting?

  • What are the most promising pipeline products, and what will be their likely uptake and patient share in NSCLC?

  • What are the NSCLC therapy market’s key drivers and constraints and how will the market evolve over the forecast period?

 

Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.

10-year market forecast (2023–2033)

Annualized drug-level sales and patient share projections across the U.S., EU5, and Japan.

Global Epidemiology & Market Segmentation

Diagnosed incidence of NSCLC by country, histology, stage and line of therapy, segmented into drug-treatable populations.

Pipeline Intelligence powered by Cortellis

Real-time updates on current and emerging therapies, including novel drug classes.

Primary research with 38 interviews with thought-leading medical oncologists

Experts perspectives on treatment adoption, unmet needs and future opportunities.

Gain a competitive edge with unparalleled insights into the NSCLC market

Ensure your strategy is informed by the latest trends, forecasts, and competitive insights in heart failure treatment.

What is Disease Landscape & Forecast?

Disease Landscape & Forecast is a premier market intelligence platform, offering:

  • Comprehensive market data including world-class epidemiology, current and emerging therapy insights, and robust drug forecasts

  • Dynamic updates ensuring continuous enhancements to reflect indication-specific developments throughout the year

  • Real-time pipeline intelligence coming directly from Cortellis, with daily updates and interactive figures for in-depth analysis

 

Already a Disease Landscape & Forecast client?

Expert insights on non-small-cell lung cancer

Built on expert knowledge and rigorous research

  • 38 thought-leading NSCLC specialists across the G7.

  • Comprehensive epidemiological modeling for non-small cell lung cancer subpopulations.

  • Real-time pipeline intelligence tracking the most promising therapies.

 

 

Request more information